A phase IV clinical trial of Licartin combined with TACE for prevention of hepatocellular carcinoma recurrence

A clinical study of antibody-targeted therapy of hepatocellular carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-11001664

Enrollment

Unknown

Registered

2011-11-02

Start date

2011-11-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

B:Conventional TACE

A:Licartin with conventional TACE

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients are entirely voluntary, good compliance, sign the informed consent form, Age 18 to 80 years; 2. Diagnosis of hepatocellular carcinoma by pathology or clinical diagnosis; 3. Barcelona Clinic Liver Cancer (BCLC) classification: stage B or C; 4. ECOG score of physical state =3*10^9/L, platelet counts >70*10^9/L; 7. No organ severe dysfunction; 8. Expected survival >=3 months.

Exclusion criteria

Exclusion criteria: 1. Allergic reactions to biological agents, hypersensitiveness; 2. Pregnancy and breast-feeding women; 3. The initial skin test-positive patients for Metuximab antibody; 4. Patients with brain metastases; 5. Patients with hypothyroidism.

Design outcomes

Secondary

Measure	Time frame
safety of Licartin for hepatocelluar carcinoma;1, 2, 3, 5-year survival rate;overall survival, OS;	—

Primary

Measure	Time frame
Time to tumor progression (TTP);3, 6, 12, 24-month recurrence rate;	—

Countries

China

Contacts

Public ContactZhi-Nan Chen

znchen@fmmu.edu.cn+86 029 84773243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026